Biovenic
Veterinary Vaccine Development - Biovenic
Veterinary Vaccine Development

Online Inquiry

Veterinary Vaccine Development

Inquiry Now

BioVenic comprehensive research and development approach encompass a wide range of infectious diseases that affect animals globally. By focusing on cutting-edge technologies, such as recombinant DNA, viral vectors, and adjuvant formulations, BioVenic ensures the design of highly effective and safe vaccines.

Our Services

Veterinary Vaccine Development Solutions by Prophylactic Type

BioVenic offers one-stop solutions for veterinary vaccine development for protecting animals against various pathogen types, including viruses, bacteria, protozoan and rickettsia, parasite, and fungus. Through professional R&D capabilities and advanced technologies, we provide effective and targeted solutions for a wide spectrum of animal-specific and zoonotic infectious diseases.

Veterinary Viral Vaccine Development

Our team focuses on innovative viral vaccine development to combat a variety of viral infections affecting animals. Our R&D platforms involves harnessing advanced technologies, such as viral vectors and recombinant DNA, to develop vaccines that are not only highly effective but also safe for different animal species.

Fig. 1 Veterinary Viral Vaccine Development. (BioVenic Autorized)

Fig. 2 Veterinary Bacterial Vaccine Development. (BioVenic Autorized)

Veterinary Bacterial Vaccine Development

We are dedicated to the development of bacterial vaccines that target a range of bacterial pathogens affecting animals. Our research and development efforts include novel approaches to antigen selection, adjuvant formulations, and delivery systems to ensure the efficacy and safety of our bacterial vaccines.

Veterinary Protozoal and Rickettsial Vaccine Development

BioVenic is at the forefront of innovation, dedicated to offering effective and targeted solutions for the development of vaccines, which effectively prevent animal diseases caused by protozoan and rickettsia. We help develop both transmission-blocking vaccines and Infection and Treatment Method (ITM) vaccines for various animal species.

Fig. 3 Veterinary Protozoal and Rickettsial Vaccine Development. (BioVenic Autorized)

Fig. 4 Veterinary Parasitic Vaccine Development. (BioVenic Autorized)

Veterinary Parasitic Vaccine Development

Our expertise extends to parasitic vaccine development, addressing animal diseases caused by these parasites. Our one-stop solution focuses on understanding the complex life cycles of these pathogens and developing veterinary vaccines that provide robust protection against their various stages.

Veterinary Fungal Vaccine Development

We are actively engaged in pioneering fungal vaccine development to help our clients address animal health R&D problems. We aim to create innovative fungal and pan-fungal vaccine development solutions that provide effective protection against various animal infectious fungal pathogens.

Fig. 5 Veterinary Fungal Vaccine Development. (BioVenic Autorized)

Innovative Veterinary Vaccine Development Solutions

BioVenic continues to push the boundaries of veterinary vaccine innovation. We are actively engaged in areas of research and development in animal reproduction and animal cancer.

Fig. 6 Innovative Veterinary Vaccine Development Solutions. (BioVenic Autorized)

We are dedicated to revolutionizing the approach to animal reproduction and management through providing R&D solutions for animal immunocastration vaccines. Our one-stop solution aims to help develop vaccines that induce a targeted and controlled immune response to achieve sterilization or alteration in reproductive functions without administration of chemical drugs or surgical procedures.

We are also committed to advancing cancer vaccine development for companion animals. Our services focus on identifying cancer-specific antigens and developing vaccines that stimulate the immune system to recognize and target cancer cells, contributing to the advancement of oncology care for companion animals.

Veterinary Vaccine Development Platforms

BioVenic employs a diverse array of vaccine development strategies to address the unique challenges posed by various pathogens affecting animals. Our commitment to innovation is reflected in the breadth of our vaccine development platforms. Please read the links in the table to learn more about our platforms for veterinary vaccine development.

Live Attenuated Veterinary Vaccine Development
BioVenic pioneers the development of live attenuated vaccines, leveraging weakened forms of pathogens to stimulate robust immune responses without causing animal infectious disease, which ensures effective protection against targeted animal infections.
Toxoid Veterinary Vaccine Development
Our offerings include services for the development of toxoid veterinary vaccines. Toxoid vaccines utilize toxins produced by disease-causing germs, fostering immunity against the specific components of the germ responsible for the disease, rather than the entire organism, which directs the animal immune response to the toxin, enhancing the veterinary vaccine's efficacy.
Gene-Deleted Attenuated Veterinary Vaccine Development
Building on the live attenuated concept, our team employs gene-deletion techniques to further enhance the safety and efficacy of vaccines by removing specific virulence genes while maintaining immunogenicity.
DNA Veterinary Vaccine Development
Based on DNA-based technologies, our team excels in developing innovative veterinary vaccines that leverage the genetic code for enhanced immunogenicity. Our veterinary DNA vaccines are designed to provide durable protection against a spectrum of infectious diseases affecting animals.
Recombinant Vectored Veterinary Vaccine Development
BioVenic help design recombinant viral vectors to deliver key antigens, triggering potent immune responses, which allows for the development of veterinary vaccines against a broad range of animal infectious pathogens.
RNA Veterinary Vaccine Development
We specialize in crafting mRNA vaccines tailored to the unique challenges presented by different animal species. Our RNA-based vaccine development services are designed to elicit robust immune responses while prioritizing safety and efficacy.
Inactivated Veterinary Vaccine Development
Our expertise extends to inactivated vaccine research and development, where animal infectious pathogens are rendered non-infectious while retaining their antigenic properties. The inactivated vaccines provide a safe and effective means of inducing protective immune responses for animals.
Phage-based Veterinary Vaccine Development
BioVenic pioneers the use of phage display and phage DNA as platforms for veterinary vaccine development. Leveraging the specificity of phages, we engineer targeted vaccines to address bacterial infections, offering a unique approach to combating veterinary pathogens.
Whole Cell Bacterin Veterinary Vaccine Development
We provide comprehensive services for the development of whole cell bacterin vaccines, supporting you throughout the entire process, including strain culture and formulation development. Our aim is to utilize the whole bacterial cells to stimulate animal immune responses, empowering animals to effectively combat bacterial infections.
Combined Veterinary Vaccine Development
Recognizing the complexity of some animal infectious pathogens, BioVenic explores combined vaccine development strategies, combining multiple techniques and approaches to achieve comprehensive animal immune protection against diverse strains or types.
Recombinant Subunit Veterinary Vaccine Development
BioVenic's dedication to precision is evident in the development of vaccines based on recombinant proteins, carbohydrate subunits, synthetic peptides, and conjugates, ensuring targeted animal immune responses against key antigens.
Autogenous Veterinary Vaccine Development
We specialize in autogenous veterinary vaccine development for personalized solutions in various animal species. We work closely with clients to design tailor-made vaccines that address specific infectious agents prevalent in specific farmed animal populations, ensuring a targeted and effective response to localized challenges.
Virus-like Particle Veterinary Vaccine Development
BioVenic offers comprehensive one-stop solution for virus-like particles (VLPs) vaccine development. Our services enable to utilize the VLPs to mimic the structure of animal infectious viruses without the genetic material, providing a safe and effective platform for veterinary vaccine development.

One-stop Services for Veterinary Vaccine Development

Fig. 7 One-stop Services for Veterinary Vaccine Development. (BioVenic Autorized)

BioVenic offers one-stop services for comprehensive veterinary vaccine development. From initial concept to pre-market products, our integrated solutions streamline the entire vaccine development process. Services include antigen discovery, identification and characterization, expression, labeling, and purification. We excel in formulation optimization, administration route and delivery system selection, ensuring efficacy for diverse animal species. Our in vitro and in vivo assessments prioritize safety and efficacy. With contract veterinary vaccine manufacturing, we bring concepts to reality. BioVenic stands as your trusted partner, providing end-to-end solutions, advancing veterinary healthcare with efficiency and excellence.

Antigen Solutions

BioVenic's antigen solution for veterinary vaccine development offers a tailored approach, encompassing veterinary antigen discovery, characterization, expression, labeling, and purification. Our advanced techniques ensure precise analysis, efficient synthesis, strategic labeling, and high-quality purification of antigens, which accelerate the development of potent veterinary vaccines.

Formulation Solutions

Our formulation solution for veterinary vaccine development excels in optimizing formulations through strategic administration route and delivery system selection. Tailored for livestock, poultry, companion animals, and aquatic species, our services ensure precision in vaccine delivery, enhancing the efficacy and safety of veterinary vaccines.

In Vitro Safety and Efficacy Assessment

We employ a diverse range of in vitro models and assays to evaluate the safety and efficacy of various types of veterinary vaccines. Our comprehensive in vivo assay services ensure a thorough understanding of vaccine candidates before progressing to in vivo studies.

In Vivo Safety and Efficacy Assessment

Our services encompass a spectrum of techniques, including various animal disease models construction, animal pathology evaluations, transmission studies, and immune response assessments, dose optimization studies, ensuring veterinary vaccine safety and effectiveness.

Contract Veterinary Vaccine Manufacturing

We offer contract veterinary vaccine manufacturing services from lab-scale to large scale, providing solution for the production of high-quality veterinary vaccines. We offer end-to-end manufacturing services, including upstream and downstream processes, facilitating efficient and reliable production and ensuring the scalability and consistency of vaccine production.

Our Advantages

Multidisciplinary Expertise

Our team comprises experts in molecular biology, animal immunology, virology, and related fields, fostering a multidisciplinary approach to veterinary vaccine development.

Cutting-edge Technology Platforms

We leverage advanced technologies in RNA and DNA vaccine development, phage-based vaccines, and autogenous solutions, ensuring our offerings support your R&D requirements.

Innovation and Improvements

BioVenic is committed to continuous research and innovation and strives to continually improve veterinary vaccine development methodologies to help prevent animal diseases and optimize animal management.

Quality Assurance

Quality assurance measures are ingrained in our processes, guaranteeing the consistency, safety, and efficacy of the veterinary vaccines we develop.

BioVenic emerges as a trusted partner for clients seeking pioneering and customized vaccine development solutions in the field of veterinary healthcare. From pathogenic antigen discovery to formulation studies, as well as in vivo and in vitro assessment, we offer comprehensive technology platforms for innovative vaccine development. Please contact us to learn more details of our capabilities in veterinary vaccine development.

Inquiry Basket